Reply to Letter to the Editor: 'Can Differences in Non-Vitamin K Antagonist Oral Anticoagulant Preferences Result in Varying Clinical Outcomes in Patients with Atrial Fibrillation?'
Anatol J Cardiol
.
2024 Jan;28(1):70.
doi: 10.14744/AnatolJCardiol.2023.4097.
Authors
Serkan Ünlü
1
,
Servet Altay
2
,
Ömer Gedikli
3
,
Özge Özden
4
,
Uğur Canpolat
5
,
Lütfü Aşkın
6
,
Çağrı Yayla
7
,
Ahmet Yanık
8
,
Hüseyin Altuğ Çakmak
9
,
Ümit Yaşar Sinan
10
,
Feyzullah Beşli
11
,
Mahmut Şahin
3
,
Seçkin Pehlivanoğlu
12
Affiliations
1
Department of Cardiology, Faculty of Medicine, Gazi University, Ankara, Türkiye.
2
Department of Cardiology, Faculty of Medicine, Trakya University, Edirne, Türkiye.
3
Department of Cardiology, Faculty of Medicine, Ondokuz Mayıs University, Samsun, Türkiye.
4
Department of Cardiology, Bakırköy Dr. Sadi Konuk Training and Research Hospital, İstanbul, Türkiye.
5
Department of Cardiology, Faculty of Medicine, Hacettepe University, Ankara, Türkiye.
6
Department of Cardiology, Faculty of Medicine, Adıyaman University, Adıyaman, Türkiye.
7
Department of Cardiology, Yüksek İhtisas Training and Research Hospital, Ankara, Türkiye.
8
Department of Cardiology, Samsun Training and Research Hospital, Samsun, Türkiye.
9
Department of Cardiology, Mustafa Kemal Paşa State Hospital, Bursa, Türkiye.
10
Institute of Cardiology, Faculty of Medicine, İstanbul University, İstanbul, Türkiye.
11
Department of Cardiology, Faculty of Medicine, Harran University, Şanlıurfa, Türkiye.
12
Department of Cardiology, Faculty of Medicine, Başkent University, İstanbul, Türkiye.
PMID:
38167800
PMCID:
PMC10796243
DOI:
10.14744/AnatolJCardiol.2023.4097
No abstract available
MeSH terms
Anticoagulants / therapeutic use
Atrial Fibrillation* / chemically induced
Atrial Fibrillation* / drug therapy
Humans
Warfarin / adverse effects
Substances
Anticoagulants
Warfarin